SIRPant Immunotherapeutics to Participate in Wells Fargo Virtual Private Biotech Symposium
April 30, 2024 08:00 ET
|
SIRPant Immunotherapeutics, Inc.
HUMMELSTOWN, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics, Inc., a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based...
SIRPant Immunotherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating SIRPant-M in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
March 12, 2024 08:00 ET
|
SIRPant Immunotherapeutics, Inc.
HUMMELSTOWN, Pa., March 12, 2024 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics, Inc., a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based...
SIRPant Immunotherapeutics Strengthens Board of Directors with Appointment of Roger Sawhney, M.D.
January 22, 2024 08:00 ET
|
SIRPant Immunotherapeutics, Inc.
HUMMELSTOWN, Pa., Jan. 22, 2024 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics, Inc., a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based immunotherapies...
SIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-MTM for the Treatment of Solid Tumors
December 12, 2023 08:00 ET
|
SIRPant Immunotherapeutics, Inc.
HUMMELSTOWN, Pa., Dec. 12, 2023 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics, Inc., a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based immunotherapies...
SIRPant Immunotherapeutics Receives FDA Orphan Drug Designation for SIRPant-M for the Treatment of T-Cell Lymphoma
November 15, 2023 09:00 ET
|
SIRPant Immunotherapeutics, Inc.
HUMMELSTOWN, Pa., Nov. 15, 2023 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics Inc, a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based immunotherapies...
SIRPant Immunotherapeutics to Present Trial in Progress Poster at the Society for Immunotherapy of Cancer 38th Annual Meeting
September 27, 2023 09:00 ET
|
Sirpant Immunotherapeutics, Inc.
HUMMELSTOWN, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics Inc, a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based immunotherapies...